Demand for Outsourcing Biologics Fill Finish Services

Th increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the steps involved in the production of biologics , fill finish is heavily outsourced activities in the pharmaceutical industry.

Biologics Fill / Finish Service Providers

Currently, it is estimated that more than 50% of the overall operations are outsourced to service providers.

Type of Biologics Fill / Finish Service Providers

Service providers offering these services are using vials for filling of biologics. Of these, over 70% of service providers operate at clinical and commercial scales of operation

Biologics Fill / Finish Service Providers Headquarted in Asia-Pacific

Of the players offering these services for biologics are headquartered in Asia-Pacific. More than 35% of these players are located in China. Further, of these, more than 40% players are well established players.

Expansion Activity in Biologics Fill / Finish Domain

Expansions have been witnessed by the industry, since 2013 to cater to the increasing need of their clients; of these, 55% expansions are associated with the establishment of new facility or adding area to the existing facility

Current Capacity of biologic fill finish

Of global biologics fill / finish capacity available in the facilities established by services providers is for filling of vials. Further, majority of capacity is available with service providers headquartered in Asia-Pacific.

Market Share

As projected by Roots Analysis, antibodies will have the highest share in this market. This trend is likely to continue in the future. In addition, majority of the market is likely to be driven by the filling of vials and syringes

More than 35% of these service providers are headquartered in Europe. Over 20% of these players were established before 1960 and 45% of the players were established after 2000.


With outsourcing being increasingly accepted as a viable / beneficial business model and the anticipated growth in the biologics market, the opportunity for fill / finish biopharmaceuticals service providers is expected to grow at a steady pace over the coming years.

For more details you can visit

For blog on “Artificial Intelligence (AI) In Oncology: Current Scenario And Future Potential” please visit

For blog on “Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders” please visit

For blog on “Intracellular Drug Delivery – Future Potential” please visit